ALLO-329

N/A

Report date: 2025/07/28 20:00:47

Base Information

Drug NameALLO-329
Drug Alias NameALLO-329
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionB-lymphocyte antigen CD19 modulatorsCD70 antigen modulators
TargetsB-lymphocyte antigen CD19CD70 antigen
Therapy Area/IndicationsAnti-synthetase SyndromeScleroderma, SystemicLupus Erythematosus, Systemic +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesAllogene Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesAllogene Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsAnti-synthetase SyndromeScleroderma, SystemicLupus Erythematosus, Systemic +[6] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A